8-K: Invivyd Launches PEMGARDA, Reports Positive Clinical Data, and Advances Pipeline

Invivyd, Inc. announced its first quarter 2024 financial results, the commercial launch of PEMGARDA for COVID-19 pre-exposure prophylaxis, and progress in its pipeline, including plans for a rapid pathway to potential treatment authorization.

Summary

• Invivyd reported its first quarter 2024 financial results, including a cash position of $189.4 million as of March 31, 2024.
• The company launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromise.
• Invivyd received product-specific reimbursement codes for PEMGARDA from the U.S. Centers for Medicare & Medicaid Services (CMS), covering approximately half of the target population.
• Interim exploratory COVID-19 clinical event data from the CANOPY Phase 3 clinical trial of VYD222 were reported, showing a potential signal of clinical protection from symptomatic COVID-19.
• The company announced plans to pursue a rapid immunobridging pathway to potential EUA for COVID-19 treatment in certain immunocompromised people, based on U.S. FDA feedback.
• Invivyd is advancing VYD2311, its next monoclonal antibody candidate, using its variant monitoring, predictive modeling, and antibody engineering technologies.
• The company expects to end 2024 with at least $75 million in cash and cash equivalents, based on anticipated 2024 net product revenue of $150-$200 million and recent resource realignment.
• Research and development expenses were $31.2 million for the quarter ended March 31, 2024, compared to $28.0 million for the same period in 2023.
• Selling, general, and administrative expenses were $14.9 million for the quarter ended March 31, 2024, compared to $11.0 million for the same period in 2023.
• The net loss for the quarter ended March 31, 2024, was $43.5 million, compared to $35.3 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the commercial launch of PEMGARDA, positive clinical data, and plans for a treatment EUA. However, the increased net loss and reliance on third parties introduce some caution.

Positives

• The launch of PEMGARDA marks a significant step for the company into the commercial phase.
• The receipt of CMS reimbursement codes for PEMGARDA is a positive development for market access.
• The interim data from the CANOPY trial suggests potential clinical efficacy of VYD222.
• The rapid immunobridging pathway for treatment EUA could accelerate the availability of a COVID-19 treatment.
• The advancement of VYD2311 demonstrates the company's commitment to innovation.
• The company has a strong cash position of $189.4 million as of March 31, 2024.
• The projected 2024 net product revenue of $150-$200 million is a positive outlook for the company's financial performance.

Negatives

• The company reported a net loss of $43.5 million for the first quarter of 2024, which is an increase from the $35.3 million loss in the same period of 2023.
• Research and development expenses increased to $31.2 million for the quarter, up from $28.0 million in the same period of 2023.
• Selling, general, and administrative expenses also increased to $14.9 million for the quarter, up from $11.0 million in the same period of 2023.

Risks

• The EUA for PEMGARDA could be revoked or revised by the FDA.
• The company's ability to maintain and expand sales, marketing, and distribution capabilities is crucial for commercial success.
• There are uncertainties related to the regulatory authorization or approval process for the COVID-19 treatment.
• The company relies on third parties for manufacturing, labeling, packaging, storing, and distributing its products.
• The company's ability to provide sufficient commercial supply of PEMGARDA to meet market demand is a risk.
• The company's ability to obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA is a risk.
• The company's ability to continue as a going concern is dependent on its ability to optimize operating expenses and secure adequate funding.

Future Outlook

Invivyd anticipates submitting an EUA application to the FDA for pemivibart for the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people using a rapid immunobridging pathway. The company expects to end 2024 with at least $75 million in cash and cash equivalents, based on anticipated 2024 net product revenue of $150-$200 million.

Management Comments

• Marc Elia, Chairman of the Invivyd Board of Directors, stated that moving into the commercial phase is a critical step for the company and they are executing on the PEMGARDA launch with maximum focus.
• Management looks forward to sharing more of the scientific underpinnings of their plans, including detail on the innovative engine they believe can deliver meaningful product-level advancements.

Industry Context

The announcement comes as the biopharmaceutical industry continues to focus on developing treatments and preventatives for COVID-19, particularly for vulnerable populations. The company's focus on monoclonal antibodies and its rapid development approach aligns with the need for effective and adaptable solutions to combat the evolving virus.

Comparison to Industry Standards

• Invivyd's approach to using immunobridging for EUA is similar to how other monoclonal antibodies were authorized during the pandemic, such as those from Regeneron and Eli Lilly.
• The company's projected revenue of $150-$200 million for 2024 is a significant target for a company in its early commercialization phase, but is dwarfed by the revenue of established players like Pfizer and Gilead in the COVID-19 treatment space.
• The company's focus on variant monitoring and predictive modeling is a key differentiator, as it aims to develop antibodies that can remain effective against emerging strains, unlike some older treatments that have lost efficacy against new variants.
• The company's R&D expenses of $31.2 million are typical for a biotech company in clinical development, but will need to be managed carefully to ensure a path to profitability.

Related Party Transactions

• The document mentions related-party amounts included in research and development expenses.

Stakeholder Impact

• Shareholders may be positively impacted by the commercial launch of PEMGARDA and the potential for a treatment EUA.
• Employees are likely to be impacted by the company's growth and commercialization efforts.
• Patients with moderate-to-severe immune compromise will benefit from the availability of PEMGARDA for COVID-19 PrEP.
• Healthcare providers will have a new option for preventing COVID-19 in high-risk patients.
• Suppliers and distributors will be impacted by the company's commercial activities.

Next Steps

• Invivyd plans to submit an EUA application for pemivibart for COVID-19 treatment.
• The company will continue to advance VYD2311 into clinical development.
• Invivyd will continue to monitor and analyze SARS-CoV-2 variants to inform future antibody development.
• The company will report PEMGARDA net product revenue with its second quarter 2024 financial results.

Key Dates

Keywords

PEMGARDA, COVID-19, monoclonal antibody, EUA, immunocompromised, PrEP, VYD222, VYD2311, immunobridging, FDA, CMS, clinical trial, variant monitoring, net product revenue